Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Alison K. Meagher"'
Autor:
S. A. Van Wart, Julie A. Passarell, Brenda Cirincione, Paul G. Ambrose, Evelyn J. Ellis-Grosse, Timothy Babinchak, Alison K. Meagher, K. Liolios
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:204-210
Exposure-response analyses were performed to test the microbiological and clinical efficacies of tigecycline in complicated intra-abdominal infections where Escherichia coli and Bacteroides fragilis are the predominant pathogens. Data from evaluable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f706835dd3268294641de2e94ba184
https://doi.org/10.1128/aac.00813-07
https://doi.org/10.1128/aac.00813-07
Autor:
Timothy Babinchak, Brenda Cirincione, S. A. Van Wart, Paul G. Ambrose, Evelyn J. Ellis-Grosse, Alison K. Meagher, Julie A. Passarell, K. Liolios
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:1939-1945
Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a777544b037d8f5564be50b39e199f86
https://doi.org/10.1128/aac.01084-06
https://doi.org/10.1128/aac.01084-06
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 52:165-171
Tigecycline is a new first-in-class glycylcycline antimicrobial agent with expanded broad-spectrum activity against both Gram-negative and Gram-positive aerobes and anaerobes, as well as atypical bacterial species. The spectrum of activity extends to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759bf1c53830a4cc0297fe83898f489f
https://doi.org/10.1016/j.diagmicrobio.2005.05.006
https://doi.org/10.1016/j.diagmicrobio.2005.05.006
Publikováno v:
Antimicrobial Agents and Chemotherapy. 48:2061-2068
The pharmacokinetics of an extended-release (XR) formulation of ciprofloxacin has been compared to that of the immediate-release (IR) product in healthy volunteers. The only significant difference in pharmacokinetic parameters between the two formula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24eb4d7cffe316e9129db120caa3178b
https://doi.org/10.1128/aac.48.6.2061-2068.2004
https://doi.org/10.1128/aac.48.6.2061-2068.2004
Autor:
Mary C. Birmingham, Gary A. Noskin, Alan Forrest, Patrick F. Smith, Alison K. Meagher, Jerome J. Schentag, Craig R Rayner
Publikováno v:
Annals of Oncology. 14:795-801
Background: Linezolid is a recently approved oxazalidinone with extended activity against Gram-positive bacteria. We evaluated the results of linezolid therapy in neutropenic cancer patients with Gram-positive bacterial infections from a compassionat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::482724635c46159f4496894feb03e213
https://doi.org/10.1093/annonc/mdg211
https://doi.org/10.1093/annonc/mdg211
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:548-553
Data obtained from 318 adult patients treated under the linezolid compassionate-use protocol were used to develop a population model of the pharmacokinetics of intravenous and oral linezolid. All of the patients received 600 mg of linezolid every 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa60872ae2b1c9dc9e0757d544f28c49
https://doi.org/10.1128/aac.47.2.548-553.2003
https://doi.org/10.1128/aac.47.2.548-553.2003
Autor:
Paul G. Ambrose, Brenda Cirincione, Sujata M. Bhavnani, Julie A. Passarell, Scott A. Van Wart, Alison K. Meagher, Evelyn J. Ellis-Grosse
Publikováno v:
Diagnostic microbiology and infectious disease. 63(2)
Correctly determined susceptibility breakpoints are important to both the individual patient and to society at large. A previously derived patient population pharmacokinetic model and Monte Carlo simulation (9999 patients) were used to create a likel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74ff4d04473b7bc63ebd5386b9aaff16
https://pubmed.ncbi.nlm.nih.gov/19150707
https://pubmed.ncbi.nlm.nih.gov/19150707
Autor:
Evelyn J. Ellis-Grosse, Alison K. Meagher, Timothy Babinchak, Paul G. Ambrose, Chris Rubino, Julie A. Passarell, Joan M. Korth-Bradley, Scott A. Van Wart, Brenda Cirincione
Publikováno v:
Diagnostic microbiology and infectious disease. 63(1)
Potential tigecycline-Enterobacteriaceae susceptibility breakpoints were evaluated using 2 approaches, which differed in the nature of the probabilities assessed by MIC value. Using a previously derived tigecycline population pharmacokinetic model an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9996915f3d32dc031c82d40a5c6c76b
https://pubmed.ncbi.nlm.nih.gov/19073300
https://pubmed.ncbi.nlm.nih.gov/19073300
Autor:
Timothy Babinchak, Julie A. Passarell, Kathryn Liolios, Elizabeth Ludwig, Evelyn J. Ellis-Grosse, Thaddeus H. Grasela, Alison K. Meagher
Publikováno v:
Diagnostic microbiology and infectious disease. 65(2)
Tigecycline exposure (area under the concentration-time curve [AUC((0-infinity))] and maximum serum concentration [C(max)]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after 12.5- to 300-mg single doses. Nausea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41fea9a6265bf328aa30426a274f054b
https://pubmed.ncbi.nlm.nih.gov/19748422
https://pubmed.ncbi.nlm.nih.gov/19748422
Autor:
Alison K. Meagher, Brenda Cirincione, S. A. Van Wart, Joel S. Owen, Joan M. Korth-Bradley, Elizabeth Ludwig
Tigecycline, a first-in-class expanded glycylcycline antimicrobial agent, has demonstrated efficacy in the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal (cIAI) infections. A population pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81036cb41b8932de392fa6a2dfb9fdb
https://europepmc.org/articles/PMC1635236/
https://europepmc.org/articles/PMC1635236/
